FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Budget Proposal Details $400 Million in Cuts

[ Price : $8.95]

FDA releases its FY 2026 budget proposal showing that the agencys overall budget would decrease by 4% ($271 million) to $6.8 billi...

Guide on Bioequivalence for Immediate-Release Drugs

[ Price : $8.95]

FDA releases a draft guidance entitled M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Bio...

Aurolife NC Drug Plant Hit With Form-483

[ Price : $8.95]

FDA issues Aurolife an 11-item Form FDA-483 following a 3/24-4/10 inspection at its Durham, NC manufacturing facility that cited s...

Group Seeks Warnings on Nuvigil, Provigil

[ Price : $8.95]

Public Citizen petitions FDA to contraindicate the use of Provigil (modafinil) and Nuvigil (armodafinil) during pregnancy because ...

Drug Firms Agree to Pay $51 Million in Pay-to-Delay Suit

[ Price : $8.95]

AstraZeneca and Handa Pharmaceuticals agree to pay $51.4 million to resolve allegations they participated in a pay-for-delay schem...

Breakthrough Status for Artificial Heart

[ Price : $8.95]

FDA grants BiVACOR a breakthrough device designation for its titanium Total Artificial Heart.

MAHA Report Questioned on Nonexistent Science

[ Price : $8.95]

Critics call out HHS secretary Robert F. Kennedy Jr.s recent Make America Healthy Again report for citing allegedly nonexistent sc...

HHS Nixes Moderna Bird Flu Vaccine Funding

[ Price : $8.95]

HHS terminates a late-stage grant award to Moderna for developing a vaccine candidate targeting the H5 bird flu.

Attorney Warns: FDA Watching Professional Promotion

[ Price : $8.95]

Attorney Nathan Downing says medical product companies should review their professional promotions as strictly as they review dire...

Patritumab BLA Pulled by Merck/Daiichi

[ Price : $8.95]

Merck and Daiichi Sankyo say they have withdrawn their BLA for the lung cancer drug patritumab deruxtecan.